STXS Stereotaxis

Stereotaxis to Report Fourth Quarter and Full Year 2019 Financial Results on March 10, 2020

Stereotaxis to Report Fourth Quarter and Full Year 2019 Financial Results on March 10, 2020

ST. LOUIS, Feb. 26, 2020 (GLOBE NEWSWIRE) -- (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 fourth quarter and full year ended December 31, 2019 on Tuesday, March 10, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.

What:Stereotaxis fourth quarter and full year 2019 financial results conference call
  
When:Tuesday, March 10, at 10:00 a.m. Eastern Time (7:00 a.m. PT)
  
Dial In Number:To access the live call, dial 800-367-2403 (US and Canada) or 334-777-6978 (International) and give the participant pass code 9066267.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at
  
Call Replay:A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through March 17, 2020. To request access for a replay of the conference call, please .

About Stereotaxis

is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit .

Company Contacts:

David L. Fischel

Chairman and Chief Executive Officer

Kimberly Peery

Chief Financial Officer

314-678-6100

 

EN
26/02/2020

Underlying

STXSStereotaxis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Con...

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the . David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings. “This is an exciting period for Stereotaxis as we achieve key regulator...

November 24, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Reports 2025 Third Quarter Financial Results

Stereotaxis Reports 2025 Third Quarter Financial Results ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial...

November 11, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearanc...

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, . GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for healthcare providers. The sys...

November 10, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis to Report Third Quarter 2025 Financial Results on November...

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025 ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis third quarter 2025 financial results conferen...

October 21, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony Sy...

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control o...

October 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch